Last edition
News about "Rexlemestrocel-L"
FDA Acknowledges Pain Reduction Data Supporting Rexlemestrocel-L Efficacy
The US Food and Drug Administration (FDA) has acknowledged clinical data showing that Rexlemestrocel-L reduced pain intensity over 12 months, supporting the product’s efficacy in treating back pain. The agency also indicated that the approval label may include language related to opioid reduction.
Rexlemestrocel-L | 19/01/2026 | By News Bureau
Mesoblast Launches FDA-Approved Ryoncil for Pediatric Graft Versus Host Disease
Mesoblast has announced the commercial launch of Ryoncil (remestemcel-L-rknd) in the United States for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients aged two months and older.
Rexlemestrocel-L | 15/09/2025 | By Dineshwori | 142
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy